Chinese Bioscience Association

Dr. Yu-Tzu Tai, a cancer biologist and immunologist, currently serves as the Director of ADC and Translational Research at Oxford BioTherapeutics in San Jose, California, and Oxford, United Kingdom. Her academic journey began with a PhD in Environmental Toxicology from the University of Wisconsin-Madison, followed by postdoctoral training at Harvard Medical School and the Dana-Farber Cancer Institute. With over two decades of experience, Dr. Tai has made significant contributions to the development of multiple FDA-approved therapies for blood and solid tumors, encompassing both small molecules and biologics. Her leadership in translational research, particularly in advancing antibody-based immunotherapies, has earned her recognition. Dr. Tai has authored over 210 scientific publications and is a long-standing member of the American Association for Cancer Research (AACR). She also serves on the editorial board of Clinical Cancer Research and actively engages in collaborations between academia and industry.

Songli Wang is a biotechnology leader dedicated to advancing medical science and improving health. With expertise in molecular biology, pharmacology, and genetics, Dr. Wang has spent over twenty years developing treatments for neurodegeneration, neuroinflammation, and metabolic disorders. Formerly a senior manager at Amgen, Dr. Wang led research teams and supported innovative therapies. Currently, Dr. Wang is Founder and CEO of BioEdge Global, a consulting firm helping biotech and pharmaceutical companies discover and develop new medicines. Wang’s work connects scientific breakthroughs with practical medical solutions, resulting in publications and collaborations across academia and industry. Dr. Wang holds a Ph.D. in Pharmacology from the University of Pennsylvania and is active in multiple scientific societies, demonstrating ongoing leadership and teamwork in science and healthcare.

Ms. Chia is currently a Senior Research Associate at Gilead Sciences working in the Virology department as a researcher on the Hepatitis B cure program. Prior to moving to the Bay Area, she was a graduate student at the University of Washington Seattle, where she earned an MS in Bioengineering and investigated the role of vascular smooth muscle cells in the calcification of the brain vasculature. She also obtained a BS in Chemical and Biomolecular Engineering from Johns Hopkins University. She joined the Chinese Bioscience Association in 2017 as a volunteer to help with videography. In her spare time, she enjoys reading and spending time with her family. Back to Top Shuming Liu (President) Dr. Shuming Liu received her doctoral degree in Medicine from Linköping Medical School in Sweden. She obtained her postdoctoral training at UCSF and worked as a scientist with expertise in molecular cell biology at BD Biosciences. Shuming is passionate about cancer research and education. She is currently the president of the Save Life and Talent Foundation, where she has devoted her time to reaching out to raise cancer awareness in communities such as schools and hospitals. Her educational seminars on cancer prevention, diagnosis, and treatment have attracted people from all over the world. Many of the attendees now belong to a growing online support group which she created to not only offer her counsel but to offer a community for those fighting cancer. Dr. Liu joined CBA at the beginning of 2019 and has been actively involved in organizing symposiums, social events, and the annual meeting. In her leisure time, she enjoys cooking, photography and traveling. Frank Zhou (Operation and membership director) Frank came to the United States from Shanghai, China. Intrinsically curious about human life, he earned a PhD in Biological Sciences at Carnegie Mellon University, where he studied functions of a tumor suppressor. Like many people in 2007, he was deeply touched by “The Last Lecture: Really Achieving Your Childhood Dreams” given by the late CMU computer science professor, Dr. Randy Pausch. After pushing back the frontiers of science for a decade, he realized the equal importance of preserving what we have in life besides exploring the unknowns in nature, especially after becoming a husband and a dad himself. Frank has been a CBA life time member since 2010 and volunteered for CBA for several years in different capacities. Lindsey Xie (Secretary) Ms. Xie is currently holding Sr. Manager position in Biometrics Department of Kite Pharma Inc., a Gilead company, with expertise in project management and SAS programming for statistical analysis to support company new drug development and FDA submission in oncology therapeutic area. She got her BS in Chemical Engineering from Hunan University and obtained MS in Statistics and MS in Bioengineering from University of Georgia. She has 10+ year hands-on working experience of statistical programming and project development in both pharmaceutical industries and CROs. She joined Chinese BioScience Association in 2017 and starting volunteering since then. She was the director of Publication for 2018 AC and responsible for AC Proceedings publication. Katherine Wang (Treasurer) Dr. Wang got her B.S. degree in Optics from Shandong University, and Ph.D. in Physics from Syracuse University. She worked as a research scientist in Neurodegenerative Diseases Center at University of Virginia. She has years of Hands-on experiences in optical engineering, DNA sequencing, protein purification, drug-protein interactions and cell culture. Professionally trained as a physicist, later she discovered that her real interest was in clinical data analysis. She is currently working as a SDTM programmer in Gilead Sciences after her years’ experience in clinical and statistical programming. Previously she worked as a certified advanced SAS programmer and data manager as well in clinical research organization. Katherine volunteered her time for CBA in 2009 and soon took over the responsibility of treasurer. She wrote articles for CBA Annual Conference news release in Chinese for three years. She also worked as a webmaster for www.cbasf.org during 2009 and 2010. In 2018, she helped publication in AC Proceedings. In her spare time, Katherine enjoys reading, writing, yoga and cuisine. Shi-An Chen (Annual Conference Co-Chair) Shi-An Chen is a Bio-X Stanford Interdisciplinary Graduate Fellow at Stanford University. He obtained his bachelor degree from National Taiwan University in Life Sciences. His research focus is scalable precision genome-editing technologies in fungal and mammalian systems. He joined CBA in 2018 and has been involved in organizing CBA events, as well as served as social chair since 2019. Shi-An is currently the president of the Asian American Graduate Student Association at Stanford University since 2019. Dannis Chang (Annual Conference Co-Chair) Dannis Chang, PharmD. is currently the Senior Director and Head of Global Medical Information and Scientific Communications at Halozyme Therapeutics, leading the development and establishment of the vision, overarching goals and objectives, and key strategic focus areas and tactics for Medical Information, Medical Communications, and Operations within Global Medical and Scientific Affairs. He received his undergraduate degree in Molecular and Cellular Biology from University of California – Berkeley, and upon graduation, he’s worked in project management at Genentech in the Translational and Molecular Oncology Division, as well as in research discovery and sales and marketing at LifeScan and AnaSpec Inc, respectively. Dannis also received a Doctor of Pharmacy (PharmD) degree from the University of Southern California and completed a post‐doctoral Fellowship with Novartis Oncology in US and Global Clinical Development and Scientific Affairs Division where he’s supported and led various efforts that involved US and Global Medical Information services, MSL Strategy and Operations, Managed Markets and Payer Access, and publications. During his fellowship, he also served as an adjunct faculty at the Ernest Mario School of Pharmacy at Rutgers University. Post fellowship training, Dannis joined Genentech as the Senior Product Lead in Medical Communications supporting Avastin in the lung, renal cell, and gynecologic cancer indications, and was accountable for the development and execution of various medical information duties. He also served as the Medical Science Director for Tecentriq in the genitourinary cancer medical team, where he’s made numerous contributions in preparation for the initial launch in 2L metastatic bladder cancer, and other launch readiness and post-market activities from a commercial and medical affairs capacity. Dannis was also the strategic program lead within Medical Business Operations, where he focused on developing system-wide capabilities to improve healthcare outcomes and enable the organization to apply the latest scientific and technological advances to resolve significant issues within the business, thus reducing operating costs and redundancies, and increase efficiencies across teams. Dannis joined Chinese Bioscience Association in 2018 as a volunteer and supported various activities such as the Cancer Immunotherapy Symposium, Member Picnic, and Annual Conference. Ying Luan (Scientific Affair Director)

Davina Chen serves as the Sponsorship Director for CBA, where she leverages her passion for community-building to foster industry partnerships and support the vibrant bioscience network in the San Francisco Bay Area. Dedicated to fostering collaboration, she focuses on connecting the dots between people and resources to drive growth across the region’s world-class biotech ecosystem. Professionally, Davina specializes in translating scientific complexity into actionable strategies that drive patient impact. As the Director of Business Strategy and Market Intelligence at Asymchem Group, she acts as a strategic enabler in the CDMO sector, bridging the gap between technical innovation and global drug development to streamline the "Bench to Bedside" continuum. With over 15 years of experience—ranging from leading regional vaccine launches to advising on AI-driven health innovations—Davina’s perspective is anchored in a multidisciplinary academic foundation, holding a BS in Agricultural Extension from National Taiwan University and an MS in Marketing from Johns Hopkins University.

Shengqin Su has been a dedicated member of CBA since 2023. He is currently a Research Scientist at Stanford University. Previously, he worked in biomarker development at Hengrui Pharmaceuticals and early colorectal cancer detection at Singlera Genomics. He received his Ph.D. in Biomedical Science and an M.S. in Applied Statistics from UW-Madison, as well as an M.S. in Nanoengineering from UC San Diego.

Jade joined CBA in 2023 and has been actively involved in organizing CBA events. Currently, she serves as a Deputy Regional Director at Biocytogen, a pre-clinical CRO specializing in gene editing, humanized animal/cell models, and disease models. With a background in the biotechnology and pharmaceutical sectors, Jade brings extensive experience in research and development from both the United States and Taiwan. Her expertise spans pre-clinical drug development and product development in sequencing-related fields. During her academic endeavors, she focused on drug repurposing for lung cancer therapeutics.

Wei-Chieh (Gala) Mu, PhD, is a Business Development Manager at Biocytogen, where she focuses on advancing preclinical research collaborations with biopharma partners. She earned her PhD in Endocrinology from the University of California, Berkeley, and previously conducted postdoctoral research at the Buck Institute for Research on Aging, applying computational and multi-omics approaches to study aging and age-related diseases. She previously served as the 2025 President of the Bay Area Taiwanese Biotechnology Association (BATBA), where she led initiatives to strengthen connections among biotech professionals in the Bay Area and foster a collaborative community.

David is a biopharmaceutical researcher with more than 10 years of experience in drug discovery, spanning cancer research, virology, and cell and gene therapy. His primary focus is preclinical cancer research for small molecule therapeutics, informed by his study of targeted therapeutics in lung cancer in the Thoracic Oncology Laboratory at UCSF. He holds a B.A. in Molecular and Cell Biology from UC Berkeley and a M.S. in Biochemistry and Molecular Biology from UCLA.

Grace is currently retired but enjoys contributing to CBA’s missions. She likes spending time with family and friends, gardening, and traveling.